Philip Reilly, M.D., J.D.
Phil Reilly joined Third Rock Ventures in 2008 to discover, launch and build companies pursuing breakthrough treatments for rare genetic diseases. He is a highly respected clinical geneticist with an extensive track record of launching and building companies in the rare disease space. He has played integral roles in several of our portfolio companies:
- Interim chief medical officer at Goldfinch Bio
- Co-founder at Fulcrum Therapeutics
- Co-founder and former interim CMO of Voyager Therapeutics
- Scientific advisory board member and former interim CMO of bluebird bio
- Co-founder and former board member of Edimer
- Co-founder and former board member of Lotus Tissue Repair (sold to Shire)
In addition to his role at Third Rock, Phil is a trustee emeritus of Cornell University, is an Overseer of Weill Cornell Medical College, and serves on the Advisory Board to the Boston University School of Public Health. Prior to joining Third Rock, he was the chief executive officer and chairman of Interleukin Genetics, and before that, he was the executive director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil has held teaching positions at Tufts University School of Medicine and Harvard Medical School. He received his B.A. from Cornell University and holds an M.D. from Yale University, a J.D. from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.
When he was much younger, Phil spent a year bartending in the Caribbean and is reported to make one of the best gin and tonics.